Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 62
Filter
1.
Health Commun ; 39(3): 493-506, 2024 Mar.
Article in English | MEDLINE | ID: mdl-36746920

ABSTRACT

Drawing upon the social amplification of risk (SARF) and the issue-attention cycle framework, we examined the amplification of COVID-19 risk-related tweets through (a) topics: key interests of discussion; (b) temperament: emotions of tweets; (c) topography (i.e., location); and (d) temporality (i.e., over time). We computationally analyzed 1,641,273 tweets, and conducted manual content analysis on a subset of 6,000 tweets to identify how topics, temperament, and topography of COVID-19 tweets were associated with risk amplification - retweet and favorite count - using negative binomial regression. We found 11 dominant COVID-19 topics-health impact, economic impact, reports of lockdowns, report of new cases, the need to stay home, coping with COVID-19, news about President Trump, government support, fight with COVID-19 by non-government entities, origins, and preventive measure in our corpus of tweets across the issue-attention cycle. The negative binomial regression results showed that at the pre-problem stage, topics on President Trump, speculation of origins, and initiatives to fight COVID-19 by non-government entities were most likely to be amplified, underscoring the inherent politicization of COVID-19 and erosion of trust in governments from the start of the pandemic. We also found that while tweets with negative emotions were consistently amplified throughout the issue-attention cycle, surprisingly tweets with positive emotions were amplified during the height of the pandemic - this counter-intuitive finding indicated signs of premature and misplaced optimism. Finally, our results showed that the locations of COVID-19 tweet amplification corresponded to the shifting COVID-19 hotspots across different continents across the issue-attention cycle. Theoretical and practical implications of risk amplification on social media are discussed.


Subject(s)
COVID-19 , Social Media , Humans , COVID-19/epidemiology , SARS-CoV-2 , Communicable Disease Control , Emotions , Attention
2.
J Pers Assess ; 104(6): 784-799, 2022.
Article in English | MEDLINE | ID: mdl-35175164

ABSTRACT

The main purpose of the study was the development of the Sensory Processing Sensitivity Questionnaire (SPSQ), designed to measure Sensory Processing Sensitivity, defined as a person's sensitivity to subtle stimuli, the depth with which these stimuli are processed, and its impact on emotional reactivity. The item pool generated for the development of the SPSQ consisted of 60 items. After exploratory factor analysis, 43 items remained, divided into six specific factors: (1) Sensory Sensitivity to Subtle Internal and External Stimuli, (2) Emotional and Physiological Reactivity, (3) Sensory Discomfort, (4) Sensory Comfort, (5) Social-Affective Sensitivity, and (6) Esthetic Sensitivity. Confirmatory factor analysis indicated that a higher-order bi-factor model consisting of two higher-order factors (a positive and negative dimension), a general sensitivity factor and six specific factors had the best fit. Strong positive associations were found between Emotional and Physiological Reactivity, the negative higher-order dimension, and Neuroticism; the same holds for the association between Esthetic Sensitivity, the positive higher-order dimension, and Openness. Emotional and Physiological Reactivity and the negative higher-order dimension showed clear associations with clinical outcomes. The relationships between the SPSQ and similar scales - the Highly Sensitive Person Scale and part of the Adult Temperament Questionnaire - were in the expected direction.


Subject(s)
Perception , Sensation , Adult , Humans , Reproducibility of Results , Surveys and Questionnaires , Factor Analysis, Statistical , Psychometrics
3.
Clin Child Psychol Psychiatry ; 27(2): 351-368, 2022 Apr.
Article in English | MEDLINE | ID: mdl-34866415

ABSTRACT

Virtual reality exposure therapy (VRET) has been commonly utilised as an extension of cognitive behavioural therapy (CBT). However, most studies examined its effectiveness among adults, with no study focusing on children with selective mutism (SM). We aimed to examine its feasibility and acceptability among children with SM. Twenty children aged 6-12 with SM diagnosis were recruited and completed six therapist-guided VRET sessions. Parents and clinicians completed measures at pre-VRET, post-VRET, 1-month and 3-month follow-up visits. At post-VRET, parent and child participants completed the acceptability questionnaires. Findings suggested the feasibility of VRET as all participants completed the programme with no attrition. Parents and child participants also reported VRET to be an acceptable and effective treatment for SM. Significant improvement in overall functioning were found at post-treatment and follow-up measures, but there were no significant changes in parent-rated speech frequency and anxiety measures. These support the acceptability of VRET as an adjunct modality (and not substitute) of CBT in SM treatment. Future studies, with more robust experimental designs and larger sample sizes, can be conducted to confirm its efficacy. As technology becomes more sophisticated, tools such as virtual environments can be explored to enhance evidence-based care for children and their families.


Subject(s)
Mutism , Virtual Reality Exposure Therapy , Adult , Anxiety/psychology , Anxiety Disorders/therapy , Child , Feasibility Studies , Humans , Mutism/therapy
4.
Proc Assoc Inf Sci Technol ; 57(1): e233, 2020.
Article in English | MEDLINE | ID: mdl-33173810

ABSTRACT

In the fight against the COVID-19 pandemic, understanding how the public responds to various initiatives is an important step in assessing current and future policy implementations. In this paper, we analyzed Twitter tweets using topic modeling to uncover the issues surrounding people's discussion of the disease. Our focus was on temporal differences in topics, prior and after the declaration of COVID-19 as a pandemic. Nine topics were identified in our analysis, each of which showed distinct levels of discussion over time. Our results suggest that as the pandemic progresses, the concerns of the public vary as new developments come to light.

5.
JMIR Serious Games ; 7(2): e13242, 2019 May 08.
Article in English | MEDLINE | ID: mdl-31066682

ABSTRACT

BACKGROUND: The rapid advancement in media technology has radically changed the way we learn and interact with one another. Games, with their engaging and interactive approach, hold promise in the delivery of knowledge and building of skills. This has potential in child and adolescent mental health work, where the lack of insight and motivation for therapy are major barriers to treatment. However, research on the use of serious games in mental health interventions for children and adolescents is still in its infancy. OBJECTIVE: This study adds to the research on serious games in mental health interventions through the development and evaluation of RegnaTales, a series of 6 mobile apps designed to help children and adolescents manage anger. We examined the usability and playability of RegnaTales, as well as children's aggression levels before and after the game play. METHODS: A total of 72 children aged between 6 and 12 years were recruited for the study. Thirty-five participants had a clinical diagnosis of disruptive behavior disorders (DBD), whereas 37 were typically developing (TD) children. Each child played 1 of the 6 RegnaTales apps for approximately 50 min before completing the Playability and Usability Questionnaire. The Reactive-Proactive Aggression Questionnaire was completed before and after the game play. RESULTS: The overall results showed high levels of enjoyment and playability. TD children and children with DBD had similar experienced fun and perceived playability scores on all 6 mobile apps. All 6 mobile apps garnered comparable experienced fun and perceived playability scores. Furthermore, 42% (5/12) to 67% (8/12) of the children indicated that they would like to play the games again. Importantly, children felt that they acquired skills in anger management, were motivated to use them in their daily lives, and felt confident that the skills would help them better manage their anger. Children reported significantly lower reactive aggression after playing the mobile apps Rage Raver (P=.001), Abaddon (P=.008), and RegnaTools (P=.03). These apps focused on the psychoeducation of the link between thoughts and emotions, as well as equipping the participants with various emotion regulation strategies such as relaxation and cognitive restructuring. CONCLUSIONS: This study presents evidence to support RegnaTales as a feasible serious game. The preliminary findings associated with reduction in reactive aggression, coupled with future research to further establish its efficacy, could warrant RegnaTales as a potential intervention for anger issues among clinical and community populations.

6.
J Am Heart Assoc ; 7(1)2018 01 04.
Article in English | MEDLINE | ID: mdl-29301757

ABSTRACT

BACKGROUND: The ACCOMPLISH (Avoiding Cardiovascular Events Through Combination Therapy in Patients Living with Systolic Hypertension) trial demonstrated that combination therapy using amlodipine, rather than hydrochlorothiazide, in conjunction with benazepril provided greater cardiovascular risk reduction among high-risk hypertensive patients. Few trials have evaluated the effect of prior antihypertensive therapy used among participants on the study outcomes. METHODS AND RESULTS: In a post hoc observational analysis, we examined the characteristics of the drug regimens taken before trial enrollment in the context of the primary composite outcome (death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, hospitalization for angina, resuscitation after sudden cardiac death, and coronary revascularization). In the "primary subgroup" (n=4475), patients previously taking any renin-angiotensin system blockade plus either a diuretic or a calcium channel blocker alone or as part of their antihypertensive regimen, there were 206 of 2193 (9.4%) versus 281 of 2282 (12.3%) primary composite events among those randomized to combination therapy involving amlodipine versus hydrochlorothiazide, respectively (adjusted Cox proportional hazard ratio, 0.74; 95% confidence interval, 0.62-0.89; P=0.0015). All other participants (n=6975) previously taking any antihypertensive regimen not included in the primary subgroup also benefited from randomization to amlodipine plus benazepril (adjusted hazard ratio, 0.84; 95% confidence interval, 0.72-0.98; P=0.024). Outcomes among most other subgroups, including patients previously taking lipid-lowering medications or dichotomized by prior blood pressure control status, showed similar results. CONCLUSIONS: When combined with an angiotensin-converting enzyme inhibitor, amlodipine provides cardiovascular risk reduction superior to hydrochlorothiazide, largely regardless of prior medication use. These findings add further support for the initial use of this combination regimen among high-risk hypertensive patients.


Subject(s)
Amlodipine/therapeutic use , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Antihypertensive Agents/therapeutic use , Benzazepines/therapeutic use , Blood Pressure/drug effects , Calcium Channel Blockers/therapeutic use , Hypertension/drug therapy , Aged , Amlodipine/adverse effects , Angiotensin-Converting Enzyme Inhibitors/adverse effects , Antihypertensive Agents/adverse effects , Benzazepines/adverse effects , Calcium Channel Blockers/adverse effects , Cause of Death , Drug Therapy, Combination , Female , Humans , Hydrochlorothiazide/therapeutic use , Hypertension/diagnosis , Hypertension/mortality , Hypertension/physiopathology , Male , Middle Aged , Randomized Controlled Trials as Topic , Risk Assessment , Risk Factors , Sodium Chloride Symporter Inhibitors/therapeutic use , Time Factors , Treatment Outcome
7.
J Cardiovasc Pharmacol ; 69(6): 374-381, 2017 Jun.
Article in English | MEDLINE | ID: mdl-28338503

ABSTRACT

We compared the systolic blood pressure (SBP)-lowering efficacy and safety of crystalline valsartan/sacubitril (LCZ696, an angiotensin receptor blocker-neprilysin inhibitor) 400 mg daily against valsartan (320 mg once daily) alone or coadministered with placebo or increasing doses of free sacubitril (50, 100, 200, or 400 mg once daily) to identify the optimal antihypertensive combination dose. This multicenter, double-blinded, 7-arm parallel-group study recruited patients with mild-to-moderate systolic hypertension (office SBP 150-179 mm Hg). Primary-dependent variable was change in office SBP from baseline to week 8. At entry (n = 907), mean age was 61.5 years, sitting office BP 160/90.2 mm Hg, and mean 24-hour ambulatory BP 142/82.1 mm Hg; 852 participants completed the study. At week 8, there were greater reductions in sitting office SBP and 24-hour ambulatory SBP with LCZ696 400 mg than with valsartan 320 mg (-5.7 and -3.4 mm Hg, respectively, P < 0.05 each). The SBP reduction with LCZ696 400 daily was similar to coadministered free valsartan 320 mg and sacubitril 200 mg. Effects were similar in those older and younger than 65 years, and active therapies had adverse event rates similar to placebo. We conclude that crystalline valsartan/sacubitril 400 mg daily (1) is superior to valsartan 320 mg daily for lowering SBP, (2) has similar efficacy to the combination of free valsartan 320 mg plus free sacubitril 200 mg, (3) represents the optimal dosage for systolic hypertension in patients of any age, and (4) is safe and well tolerated.


Subject(s)
Aminobutyrates/administration & dosage , Angiotensin II Type 1 Receptor Blockers/administration & dosage , Antihypertensive Agents/administration & dosage , Blood Pressure/drug effects , Hypertension/drug therapy , Protease Inhibitors/administration & dosage , Tetrazoles/administration & dosage , Valsartan/administration & dosage , Aged , Aminobutyrates/adverse effects , Angiotensin II Type 1 Receptor Blockers/adverse effects , Antihypertensive Agents/adverse effects , Argentina , Biphenyl Compounds , Double-Blind Method , Drug Combinations , Europe , Female , Humans , Hypertension/diagnosis , Hypertension/physiopathology , India , Male , Middle Aged , Neprilysin/antagonists & inhibitors , Neprilysin/metabolism , North America , Protease Inhibitors/adverse effects , Republic of Korea , Systole , Tetrazoles/adverse effects , Time Factors , Treatment Outcome , Valsartan/adverse effects
8.
Hypertension ; 69(3): 411-420, 2017 03.
Article in English | MEDLINE | ID: mdl-28093466

ABSTRACT

Effective treatment of systolic hypertension in elderly patients remains a major therapeutic challenge. A multicenter, double-blind, randomized controlled trial with sacubitril/valsartan (LCZ696), a first-in-class angiotensin receptor neprilysin inhibitor, was conducted to determine its effects versus olmesartan (angiotensin receptor blocker) on central aortic pressures, in elderly patients (aged ≥60 years) with systolic hypertension and pulse pressure >60 mm Hg, indicative of arterial stiffness. Patients (n=454; mean age, 67.7 years; mean seated systolic blood pressure, 158.6 mm Hg; mean seated pulse pressure, 69.7 mm Hg) were randomized to receive once-daily sacubitril/valsartan 200 mg or olmesartan 20 mg, force titrated to double the initial doses after 4 weeks, before primary assessment at 12 weeks. The study extended double-blind treatment for 12 to 52 weeks, during which amlodipine (2.5-5 mg) and subsequently hydrochlorothiazide (6.25-25 mg) were added-on for patients not achieving blood pressure target (<140/90). At week 12, sacubitril/valsartan reduced central aortic systolic pressure (primary assessment) greater than olmesartan by -3.7 mm Hg (P=0.010), further corroborated by secondary assessments at week 12 (central aortic pulse pressure, -2.4 mm Hg, P<0.012; mean 24-hour ambulatory brachial systolic blood pressure and central aortic systolic pressure, -4.1 mm Hg and -3.6 mm Hg, respectively, both P<0.001). Differences in 24-hour ambulatory pressures were pronounced during sleep. After 52 weeks, blood pressure parameters were similar between treatments (P<0.002); however, more patients required add-on antihypertensive therapy with olmesartan (47%) versus sacubitril/valsartan (32%; P<0.002). Both treatments were equally well tolerated. The PARAMETER study (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin Receptor Blocker Measuring Arterial Stiffness in the Elderly), for the first time, demonstrated superiority of sacubitril/valsartan versus olmesartan in reducing clinic and ambulatory central aortic and brachial pressures in elderly patients with systolic hypertension and stiff arteries.


Subject(s)
Aminobutyrates/administration & dosage , Hemodynamics/drug effects , Hypertension/drug therapy , Imidazoles/administration & dosage , Tetrazoles/administration & dosage , Aged , Angiotensin II Type 1 Receptor Blockers/administration & dosage , Angiotensin Receptor Antagonists/administration & dosage , Biphenyl Compounds , Dose-Response Relationship, Drug , Double-Blind Method , Drug Combinations , Female , Follow-Up Studies , Humans , Hypertension/physiopathology , Male , Middle Aged , Prospective Studies , Systole , Time Factors , Treatment Outcome , Valsartan
9.
J Clin Hypertens (Greenwich) ; 19(2): 143-150, 2017 Feb.
Article in English | MEDLINE | ID: mdl-27587277

ABSTRACT

The effects of race and age on 24-hour mean ambulatory systolic blood pressure (maSBP) responses to sequential 4-week periods of angiotensin receptor blocker therapy (valsartan [VAL] 160 mg/d then 320 mg/d and combination VAL/hydrochlorothiazide [HCTZ] 320/12.5 mg/d) were compared in 304 patients with stage 1 or 2 hypertension. There were lesser blood pressure (BP) responses from baseline with VAL monotherapy in black than Caucasian patients (-2.9 and -4.0 mm Hg vs -8.2 and -9.3 mm Hg, respectively; P<.001 each) but VAL/HCTZ BP responses were similar in both groups (-12 vs -15 mm Hg). Participants 65 years and older had lower BP responses with VAL 160 mg/d and 320 mg/d than those younger than 65 years (-2.8 and -4.5 mm Hg vs -6.5 and -7.5 mm Hg, respectively; P<.001) but similar responses to VAL/HCTZ (-14 vs -17 mm Hg). No BP response differences were found between those older than and those younger than 55 years. The authors conclude that: (1) adding low-dose HCTZ (12.5 mg daily) to VAL is more effective than VAL titration, irrespective of age or race, (2) VAL BP efficacy is lower in blacks than Caucasians, and (3) ARB responses are diminished in patients older than 65 years. Guidelines for stage 1 or 2 hypertension that suggest age 55 should determine initial monotherapy choice (eg, ARB vs thiazide diuretic) or that fail to recommend initial ARB-thiazide combination therapy should be reconsidered.


Subject(s)
Antihypertensive Agents/administration & dosage , Black or African American/statistics & numerical data , Hydrochlorothiazide/administration & dosage , Hypertension/drug therapy , Valsartan/administration & dosage , White People/statistics & numerical data , Adult , Age Factors , Aged , Aged, 80 and over , Antihypertensive Agents/therapeutic use , Double-Blind Method , Drug Therapy, Combination , Female , Humans , Hydrochlorothiazide/therapeutic use , Hypertension/ethnology , Male , Middle Aged , Treatment Outcome , Valsartan/therapeutic use , Young Adult
10.
J Clin Hypertens (Greenwich) ; 18(4): 299-307, 2016 Apr.
Article in English | MEDLINE | ID: mdl-27060568

ABSTRACT

To evaluate the effects of achieved systolic blood pressure (SBP) during treatment on cardiovascular (CV) outcomes, the authors measured event rates of a composite primary endpoint (CV death or nonfatal myocardial infarction or stroke) at on-treatment SBPs of ≥140 mm Hg and the 10 mm Hg intervals of <140 mm Hg, <130 mm Hg, and <120 mm Hg in 6459 patients with diabetes (mean age, 67) and 4246 patients without diabetes (mean age, 69) from the Avoiding Cardiovascular Events in Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial. In the diabetic cohort, the primary endpoint was 49% lower (P<.001) at <140 mm Hg than at ≥140 mm Hg, and the separate components of this endpoint were also significantly reduced. Further SBP reductions did not improve outcomes, and at <120 mm Hg they were no longer different (except for stroke) from ≥140 mm Hg. In contrast, in the nondiabetic cohort, the primary endpoint event rate fell steadily (although not significantly) through the decreasing SBP categories until it was reduced by 45% (P=.0413) at <120 mm Hg. Total stroke rates for both the diabetic (-56%, P=.0120) and nondiabetic (-68%, P=.0067) cohorts were lowest at <120 mm Hg, and adverse renal events (serum creatinine increase ≥50%) were significantly lowest in the range of 130 mm Hg to 139 mm Hg for both cohorts. Diabetic patients (<140 mm Hg or <130 mm Hg) and nondiabetic patients (<120 mm Hg) may require different SBP targets for optimal CV protection, although stroke and renal considerations should also influence the selection of blood pressure targets.


Subject(s)
Antihypertensive Agents/therapeutic use , Blood Pressure/drug effects , Diabetes Mellitus, Type 2/complications , Hypertension/drug therapy , Myocardial Infarction/etiology , Risk Assessment/methods , Stroke/etiology , Aged , Blood Pressure Determination , Diabetes Mellitus, Type 2/physiopathology , Double-Blind Method , Drug Therapy, Combination , Female , Follow-Up Studies , Humans , Hypertension/complications , Hypertension/physiopathology , Incidence , Male , Myocardial Infarction/epidemiology , Prospective Studies , Risk Factors , Stroke/epidemiology , Survival Rate/trends , Systole , Treatment Outcome , United States/epidemiology
11.
Eur Heart J ; 37(12): 955-64, 2016 Mar 21.
Article in English | MEDLINE | ID: mdl-26590384

ABSTRACT

AIMS: Recent hypertension guidelines recommend that also in high cardiovascular (CV) risk, hypertensive patients blood pressure (BP) is lowered to <140/90 mmHg as no evidence is available supporting the lower target of <130/80 mmHg recommended in previous guidelines. Whether this represents the optimal treatment strategy is debated, however. METHODS AND RESULTS: The high CV risk hypertensive patients of the Valsartan Antihypertensive Long-term use Evaluation (VALUE) trial were divided into subgroups according to (i) the percentage of on-treatment visits in which BP was reduced to <140/90 or <130/80 mmHg or (ii) the mean systolic or diastolic BP (SBP/DBP) values achieved during the entire treatment period or up to the occurrence of an event. A progressive increase from <25 to ≥75% of the visits in which BP was <140/90 mmHg was accompanied by a significant, progressive marked decrease in the covariate adjusted risk of CV morbidity and mortality, cause specific CV events (myocardial infarction, heart failure, and stroke), and all-cause mortality. Except for a persistent progressive decrease in stroke, no significant trend to a risk decrease occurred for a similar progressive increment of the proportion of visits with BP <130/80 mmHg. Increasing the proportion of visits with a BP <140/90 mmHg (but not <130/80 mmHg) was accompanied by a decreased risk of events also when differences in baseline risk were adjusted using a propensity score. Finally, compared with patients remaining at a mean on-treatment SBP ≥140 or DBP ≥90 mmHg, the risk of all events was markedly reduced when on-treatment mean SBP was lowered to a mean SBP of 130-139 mmHg or a mean DBP of 80-89 mmHg, whereas at on-treatment mean SBP <130 mmHg or DBP <80 mmHg, an additional risk reduction was found for stroke but for any other type of event, the risk of which remained similar or only slightly greater than that seen at the higher BP target. CONCLUSIONS: In the high CV risk, hypertensives of the VALUE trial reducing BP consistently to <140/90 mmHg had marked beneficial effects both when data were calculated as proportion of visits at BP target or as on-treatment mean BP. Reducing BP to <130/80 mmHg led only to some possible further benefit on stroke, whereas the risk of other outcomes remained substantially similar to or slightly greater than that seen at the higher target. Thus, aggressive BP reductions when CV risk is high may not offer substantial advantages, except perhaps in patients or conditions in which stroke risk is particularly common.


Subject(s)
Antihypertensive Agents/therapeutic use , Hypertension/drug therapy , Valsartan/therapeutic use , Aged , Blood Pressure/drug effects , Blood Pressure/physiology , Female , Humans , Hypertension/mortality , Hypertension/physiopathology , Male , Myocardial Infarction/mortality , Myocardial Infarction/physiopathology , Myocardial Infarction/prevention & control , Risk Factors , Stroke/mortality , Stroke/physiopathology , Stroke/prevention & control , Treatment Outcome
13.
J Hypertens ; 33(2): 385-92, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25259546

ABSTRACT

OBJECTIVE: Studies suggest that bedtime dosing of an angiotensin-converting enzyme (ACE)-inhibitor or angiotensin receptor blocker shows a more sustained and consistent 24-h antihypertensive profile, including greater night-time blood pressure (BP) reduction. We compared the antihypertensive effects of morning (a.m.) and evening (p.m.) dosing of valsartan on 24-h BP. METHODS: This 26-week, multicentre, randomized, double-blind study evaluated the efficacy and safety of valsartan 320 mg, dosed a.m. or p.m., versus lisinopril 40 mg (a.m.), a long-acting ACE-inhibitor, in patients with grade 1-2 hypertension and at least one additional cardiovascular risk factor. Patients (n = 1093; BP = 156 ±â€Š11/91 ±â€Š8 mmHg; 62 years, 56% male, 99% white) received (1 : 1 : 1) valsartan 160 mg a.m. or p.m. or lisinopril 20 mg a.m. for 4 weeks, then force-titrated to double the initial dose for 8 weeks. At Week 12, hydrochlorothiazide (HCTZ) 12.5 mg was added for 14 weeks if office BP was more than 140/90 mmHg and/or ambulatory BP more than 130/80 mmHg. RESULTS: Mean 24-h ambulatory SBP change from baseline to Weeks 12 and 26 was comparable between valsartan a.m. (-10.6 and -13.3 mmHg) and p.m. (-9.8 and -12.3 mmHg) and lisinopril (-10.7 and -13.7 mmHg). There was no benefit of valsartan p.m. versus a.m. on night-time BP, early morning BP and morning BP surge. Evening dosing also did not improve BP lowering in patients requiring add-on HCTZ or in nondippers at baseline. All treatments were well tolerated. CONCLUSION: Once-daily dosing of valsartan 320 mg results in equally effective 24-h BP efficacy, regardless of dosing time. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00241124.


Subject(s)
Antihypertensive Agents/administration & dosage , Blood Pressure/drug effects , Hypertension/drug therapy , Valsartan/administration & dosage , Adult , Aged , Angiotensin II Type 1 Receptor Blockers/administration & dosage , Angiotensin-Converting Enzyme Inhibitors/administration & dosage , Blood Pressure Monitoring, Ambulatory , Cardiovascular Diseases/drug therapy , Double-Blind Method , Humans , Hydrochlorothiazide/administration & dosage , Lisinopril/administration & dosage , Male , Middle Aged , Risk Factors , Treatment Outcome
14.
J Clin Hypertens (Greenwich) ; 17(2): 141-6, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25529596

ABSTRACT

Pulse pressure (PP) is an independent risk factor for cardiovascular (CV) disease and death but few studies have investigated the effect of antihypertensive treatments in relation to PP levels before treatment. The Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial showed that the combination of benazepril+amlodipine (B+A) is superior to benazepril+hydrochlorothiazide (B+H) in reducing CV events. We aimed to investigate whether the treatment effects in the ACCOMPLISH trial were dependent on baseline PP. High-risk hypertensive patients (n=11,499) were randomized to double-blinded treatment with single-pill combinations of either B+A or B+H and followed for 36 months. Patients were divided into tertiles according to their baseline PP and events (CV mortality/myocardial infarction or stroke) were compared. Hazard ratios (HRs) for the treatment effect (B+A over B+H) were calculated in a Cox regression model with age, coronary artery disease, and diabetes mellitus as covariates and were compared across the tertiles. The event rate was increased in the high tertile of PP compared with the low tertile (7.2% vs 4.4% P<.01). In the high and medium PP tertiles, HRs were 0.75 (95% confidence interval [CI], 0.60-0.95; P=.018) and 0.74 (CI, 0.56-0.98, P=.034), respectively, in favor of B+A. There was no significant difference between the treatments in the low tertile and no significant differences in treatment effect when comparing the HRs between tertiles of PP. B+A has superior CV protection over B+H in high-risk hypertensive patients independent of baseline PP although the absolute treatment effect is enhanced in the higher tertiles of PP where event rates are higher.


Subject(s)
Amlodipine/therapeutic use , Antihypertensive Agents/therapeutic use , Benzazepines/therapeutic use , Hydrochlorothiazide/therapeutic use , Hypertension/drug therapy , Aged , Amlodipine/pharmacology , Antihypertensive Agents/pharmacology , Benzazepines/pharmacology , Blood Pressure/drug effects , Blood Pressure/physiology , Double-Blind Method , Drug Therapy, Combination , Female , Humans , Hydrochlorothiazide/pharmacology , Hypertension/complications , Hypertension/physiopathology , Incidence , Male , Middle Aged , Myocardial Infarction/epidemiology , Retrospective Studies , Risk Factors , Stroke/epidemiology , Treatment Outcome
15.
BMJ Open ; 4(2): e004254, 2014 Feb 04.
Article in English | MEDLINE | ID: mdl-24496699

ABSTRACT

INTRODUCTION: Hypertension in elderly people is characterised by elevated systolic blood pressure (SBP) and increased pulse pressure (PP), which indicate large artery ageing and stiffness. LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor (ARNI), is being developed to treat hypertension and heart failure. The Prospective comparison of Angiotensin Receptor neprilysin inhibitor with Angiotensin receptor blocker MEasuring arterial sTiffness in the eldERly (PARAMETER) study will assess the efficacy of LCZ696 versus olmesartan on aortic stiffness and central aortic haemodynamics. METHODS AND ANALYSIS: In this 52-week multicentre study, patients with hypertension aged ≥60 years with a mean sitting (ms) SBP ≥150 to <180 and a PP>60 mm Hg will be randomised to once daily LCZ696 200 mg or olmesartan 20 mg for 4 weeks, followed by a forced-titration to double the initial doses for the next 8 weeks. At 12-24 weeks, if the BP target has not been attained (msSBP <140 and ms diastolic BP <90 mm Hg), amlodipine (2.5-5 mg) and subsequently hydrochlorothiazide (6.25-25 mg) can be added. The primary and secondary endpoints are changes from baseline in central aortic systolic pressure (CASP) and central aortic PP (CAPP) at week 12, respectively. Other secondary endpoints are the changes in CASP and CAPP at week 52. A sample size of 432 randomised patients is estimated to ensure a power of 90% to assess the superiority of LCZ696 over olmesartan at week 12 in the change from baseline of mean CASP, assuming an SD of 19 mm Hg, the difference of 6.5 mm Hg and a 15% dropout rate. The primary variable will be analysed using a two-way analysis of covariance. ETHICS AND DISSEMINATION: The study was initiated in December 2012 and final results are expected in 2015. The results of this study will impact the design of future phase III studies assessing cardiovascular protection. CLINICAL TRIALS IDENTIFIER: EUDract number 2012-002899-14 and ClinicalTrials.gov NCT01692301.


Subject(s)
Aminobutyrates/therapeutic use , Angiotensin II Type 1 Receptor Blockers/therapeutic use , Hypertension/drug therapy , Imidazoles/therapeutic use , Tetrazoles/therapeutic use , Vascular Stiffness/drug effects , Aged , Biphenyl Compounds , Double-Blind Method , Drug Combinations , Drug Monitoring , Female , Hemodynamics/drug effects , Humans , Male , Middle Aged , Neprilysin/antagonists & inhibitors , Prospective Studies , Research Design , Treatment Outcome , Valsartan
16.
Am J Ther ; 20(1): 2-12, 2013 Jan.
Article in English | MEDLINE | ID: mdl-22248871

ABSTRACT

A clinical trial showed comparable blood pressure (BP) lowering by valsartan/hydrochlorothiazide and amlodipine/hydrochlorothiazide in obese hypertensive patients. Relative to amlodipine/hydrochlorothiazide, valsartan/hydrochlorothiazide reduced the hyperglycemic response to glucose challenge. An objective of this post hoc analysis was to determine whether this benefit extended to African Americans and whites. Treatments (160/12.5 mg of valsartan/hydrochlorothiazide force titrated to 320/25 mg of valsartan/hydrochlorothiazide at week 4 or 12.5 mg of hydrochlorothiazide force titrated to 25 mg of hydrochlorothiazide at week 4 with 5 and 10 mg of amlodipine added at weeks 8 and 12, respectively) were administered once daily. Both treatments reduced clinic BP from baseline to all visits (P < 0.0001), regardless of race/ethnicity (126 African Americans, 212 whites). In African Americans, there were no significant between-treatment differences in clinic or ambulatory BP lowering at weeks 8 or 16. Whites responded better to valsartan/hydrochlorothiazide. In both racial/ethnic subgroups, the addition of valsartan but not amlodipine mitigated the hyperglycemic response to hydrochlorothiazide through enhanced insulin secretion. Valsartan/hydrochlorothiazide was as effective as amlodipine/hydrochlorothiazide was in reducing BP in obese, hypertensive African Americans and better than amlodipine/hydrochlorothiazide in whites. In both racial/ethnic subgroups, the addition of valsartan to hydrochlorothiazide reduced the negative metabolic effects associated with thiazide therapy.


Subject(s)
Angiotensin II Type 1 Receptor Blockers/therapeutic use , Antihypertensive Agents/therapeutic use , Black or African American , Diuretics/therapeutic use , Hypertension/drug therapy , Obesity, Abdominal/complications , White People , Adult , Aged , Aged, 80 and over , Amlodipine/therapeutic use , Biomarkers/blood , Blood Glucose/metabolism , Double-Blind Method , Drug Administration Schedule , Drug Therapy, Combination , Female , Humans , Hydrochlorothiazide/adverse effects , Hydrochlorothiazide/therapeutic use , Hyperglycemia/blood , Hyperglycemia/chemically induced , Hyperglycemia/prevention & control , Hypertension/blood , Hypertension/complications , Hypertension/ethnology , Insulin/blood , Intention to Treat Analysis , Male , Middle Aged , Obesity, Abdominal/blood , Obesity, Abdominal/ethnology , Prediabetic State/blood , Prediabetic State/complications , Prediabetic State/ethnology , Tetrazoles/therapeutic use , Treatment Outcome , Valine/analogs & derivatives , Valine/therapeutic use , Valsartan
17.
Int J Offender Ther Comp Criminol ; 57(2): 191-207, 2013 Feb.
Article in English | MEDLINE | ID: mdl-22158911

ABSTRACT

In this study, the authors compared logistic regression and predictive data mining techniques such as decision trees (DTs), artificial neural networks (ANNs), and support vector machines (SVMs), and examined these methods on whether they could discriminate between adolescents who were charged or not charged for initial juvenile offending in a large Asian sample. Results were validated and tested in independent samples with logistic regression and DT, ANN, and SVM classifiers achieving accuracy rates of 95% and above. Findings from receiver operating characteristic analyses also supported these results. In addition, the authors examined distinct patterns of occurrences within and across classifiers. Proactive aggression and teacher-rated conflict consistently emerged as risk factors across validation and testing data sets of DT and ANN classifiers, and logistic regression. Reactive aggression, narcissistic exploitativeness, being male, and coming from a nonintact family were risk factors that emerged in one or more of these data sets across classifiers, while anxiety and poor peer relationships failed to emerge as predictors.


Subject(s)
Data Mining/methods , Decision Trees , Juvenile Delinquency/psychology , Neural Networks, Computer , Support Vector Machine , Adolescent , Aged, 80 and over , Aggression/psychology , Anxiety Disorders/diagnosis , Anxiety Disorders/psychology , Child , Crime/legislation & jurisprudence , Crime/psychology , Data Mining/legislation & jurisprudence , Female , Humans , Juvenile Delinquency/legislation & jurisprudence , Juvenile Delinquency/prevention & control , Male , Personality Disorders/diagnosis , Personality Disorders/psychology , ROC Curve , Risk Factors , Secondary Prevention , Singapore , Statistics as Topic , Surveys and Questionnaires
18.
J Clin Hypertens (Greenwich) ; 14(11): 773-8, 2012 Nov.
Article in English | MEDLINE | ID: mdl-23126349

ABSTRACT

Postmenopausal women are at greater risk for hypertension-related cardiovascular disease. Antihypertensive therapy may help alleviate arterial stiffness that represents a potential modifiable risk factor of hypertension. This randomized controlled study investigated the difference between an angiotensin receptor blocker and a calcium channel blocker in reducing arterial stiffness. Overall, 125 postmenopausal hypertensive women (age, 61.4 ± 6 years; systolic blood pressure/diastolic blood pressure [SBP/DBP], 158 ± 11/92 ± 9 mm Hg) were randomized to valsartan 320 mg ± hydrochlorothiazide (HCTZ) (n = 63) or amlodipine 10 mg ± HCTZ (n = 62). The primary outcome was carotid-to-femoral pulse wave velocity (PWV) changes after 38 weeks of treatment. Both treatments lowered peripheral blood pressure (BP) (-22.9/-10.9 mm Hg for valsartan and -25.2/-11.7 mm Hg for amlodipine, P = not significant) and central BP (-15.7/-7.6 mm Hg for valsartan and -19.2/-10.3 mm Hg for amlodipine, P<.05 for central DBP). Both treatments similarly reduced the carotid-femoral PWV (-1.9 vs -1.7 m/s; P = not significant). Amlodipine was associated with a higher incidence of peripheral edema compared with the valsartan group (77% vs 14%, P<.001). BP lowering in postmenopausal women led to a reduction in arterial stiffness as assessed by PWV measurement. Both regimens reduced PWV to a similar degree after 38 weeks of treatment despite differences in central BP lowering, suggesting that the effect of valsartan on PWV is mediated through nonhemodynamic effects.


Subject(s)
Amlodipine/pharmacology , Angiotensin II Type 1 Receptor Blockers/pharmacology , Calcium Channel Blockers/pharmacology , Hypertension/diagnosis , Hypertension/drug therapy , Pulse Wave Analysis , Tetrazoles/pharmacology , Valine/analogs & derivatives , Vascular Stiffness/drug effects , Aged , Amlodipine/therapeutic use , Angiotensin II Type 1 Receptor Blockers/therapeutic use , Blood Pressure/drug effects , Calcium Channel Blockers/therapeutic use , Double-Blind Method , Female , Humans , Male , Middle Aged , Postmenopause/physiology , Tetrazoles/therapeutic use , Valine/pharmacology , Valine/therapeutic use , Valsartan
19.
J Hypertens ; 30(11): 2213-22, 2012 Nov.
Article in English | MEDLINE | ID: mdl-23011525

ABSTRACT

OBJECTIVES: To determine whether blood pressure (BP) control in hypertensive patients achieved with combination drug therapy provides the same cardiovascular benefits as with single-agent therapy. BACKGROUND: Drug combinations, most often including hydrochlorothiazide (HCTZ), are now recommended for routine BP management, but their effects on cardiovascular event rates have not been compared with effective monotherapy. METHODS: We conducted retrospective analyses of the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) data. VALUE compared cardiovascular event rates of valsartan and amlodipine. Patients with BPs not controlled (<140/90  mmHg) by the single agents had HCTZ and, if required, additional drugs of different classes, added. Using data pooled from the two treatment arms, we have now divided patients into those controlled on monotherapy and those controlled or not controlled by combination therapy. The primary study endpoint was first occurrence of cardiovascular death or nonfatal myocardial infarction or stroke. Comparisons between groups were by Cox regression, adjusted for on-treatment BP, age, prior cardiovascular events and left ventricular hypertrophy; the comparison between the monotherapy and combination therapy controlled groups was based on events occurring after 3 months by when the decision to use monotherapy or combination therapy was made. RESULTS: The primary endpoint occurred in 505 of 5924 (8.5%) monotherapy and 511 of 4621 (11.1%) combination therapy controlled patients: hazard ratio was 0.80 [95% confidence interval (CI) 0.70-0.90]. If these two groups were matched for baseline BPs and all events included from study baseline, the hazard ratio was 0.76 (95% CI 0.67-0.86). The difference between combination controlled and uncontrolled [434 of 3390 (12.8%)] groups was not significant [hazard ratio 0.90 (95% CI 0.80-1.03], nor when they were matched for baseline BPs [hazard ratio 0.95 (95% CI 0.81-1.11)]. CONCLUSION: Independent of prior cardiovascular history or baseline BP, hypertensive patients requiring combination therapy, which includes a thiazide diuretic for BP control, have a poorer cardiovascular prognosis than those controlled by monotherapy and only a nonsignificantly lower event rate than noncontrolled patients.


Subject(s)
Antihypertensive Agents/administration & dosage , Hypertension/drug therapy , Aged , Amlodipine/administration & dosage , Blood Pressure/drug effects , Cardiovascular Diseases/mortality , Cardiovascular Diseases/prevention & control , Double-Blind Method , Drug Therapy, Combination , Female , Humans , Hydrochlorothiazide/administration & dosage , Hypertension/physiopathology , Kaplan-Meier Estimate , Male , Middle Aged , Myocardial Infarction/prevention & control , Prognosis , Retrospective Studies , Stroke/prevention & control , Tetrazoles/administration & dosage , Treatment Outcome , Valine/administration & dosage , Valine/analogs & derivatives , Valsartan
20.
J Clin Hypertens (Greenwich) ; 14(7): 415-21, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22747613

ABSTRACT

The authors previously reported that addition of valsartan ameliorated the negative metabolic effects of hydrochlorothiazide in obese hypertensive patients through an enhanced postprandial insulin response. In this secondary analysis, the authors tested whether this enhanced insulin response to valsartan/hydrochlorothiazide was influenced by serum potassium levels, which were reduced to a lesser extent, when compared with amlodipine/hydrochlorothiazide. Results showed that the early insulin response with valsartan plus hydrochlorothiazide occurred regardless of serum potassium levels. Heightened insulin response was, however, not significantly different when patients with normal potassium (>3.9 mEq/L) at baseline and low potassium (≤3.9 mEq/L) at the end of the study were compared with the amlodipine/hydrochlorothiazide group. Despite the influence of serum potassium on insulin secretory response to a glucose challenge, the addition of valsartan maintained normoglycemia in patients given hydrochlorothiazide. Thus, the metabolic response to hydrochlorothiazide was improved with addition of valsartan through an enhanced insulin response that was not greatly affected by changes in potassium levels.


Subject(s)
Antihypertensive Agents/pharmacology , Diuretics/pharmacology , Hydrochlorothiazide/pharmacology , Potassium/blood , Renin-Angiotensin System/drug effects , Tetrazoles/pharmacology , Valine/analogs & derivatives , Aged , Antihypertensive Agents/administration & dosage , Blood Glucose/drug effects , Diuretics/administration & dosage , Dose-Response Relationship, Drug , Drug Therapy, Combination , Female , Glucose Tolerance Test , Humans , Hydrochlorothiazide/administration & dosage , Hypertension/drug therapy , Hypertension/pathology , Insulin/blood , Male , Middle Aged , Obesity, Abdominal , Outpatients , Postprandial Period , Statistics as Topic , Tetrazoles/administration & dosage , Valine/administration & dosage , Valine/pharmacology , Valsartan
SELECTION OF CITATIONS
SEARCH DETAIL
...